ClinicalTrials.gg
Sign In

Drug

CDX-301 clinical trials

Also written CDX-301.

A product of flt3 ligand protein; its studies count on that page too.

studies test it
10
open now
2
in phase 3
0
first study started
2011

Keep track of what changes. Save the CDX-301 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

CDX-301
6

Combined with it in one product

glembatumumab vedotin and CDX-301
1
Cohort 4
1
CDX-301 and plerixafor
1

Studies by the year they started

10 studies that test it; most in 2014 (3)

Studies that test CDX-301, by start year
YearStudies
20111
20143
20161
20191
20201
20211
20222

By phase

A phase 1/2 study counts in both.

Phase 1
5
Phase 2
6

What it is tested for

Each study’s main condition, where its own words name it.

Prostatic Neoplasms
2
Breast Neoplasms
2
Carcinoma, Non-Small-Cell Lung
1
Lymphoma, B-Cell
1
Pancreatic Neoplasms
1
Melanoma
1
Leukemia
1

Who runs them

Industry 3 · Other 7

Celldex Therapeutics (3) · Ashutosh Kumar Tewari (1) · Montefiore Medical Center (1) · Parker Institute for Cancer Immunotherapy (1) · Joshua Brody (1) · University of Texas Southwestern Medical Center (1) · Weill Medical College of Cornell University (1) · Washington University School of Medicine (1)

Often tested with

Tested in the same studies.

Poly ICLC (2) · Bempegaldesleukin (1) · DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151 (1) · CDX-1140 (1) · Glembatumumab vedotin (1) · Varlilumab (1) · Plerixafor (1)

Studies

Open first, then newest update. How each study uses CDX-301 is read from its arms, and is right about nine times in ten.

Testing it · 10

Given in every arm · 2 — CDX-301 is usual care beside what is tested